Listening...

Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. EMEA Innovative Medicine /
    2. Newsroom/
    3. Oncology/
    4. Janssen Presents Longer-Term Data for TECVAYLI®▼ (teclistamab) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma
    Oncology

    Janssen Presents Longer-Term Data for TECVAYLI®▼ (teclistamab) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

    Janssen Presents Longer-Term Data for TECVAYLI®▼ (teclistamab) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma